[Treatment of colorectal cancer. Pharmaco-economic aspects].
Cancer patients care is mainly based on scientific studies, but sometimes approaches are empiric. Rapid growth of health care expenses force the physician to take pharmacoeconomic aspects into consideration. New clinical studies have to analyse clinical benefits but also cost-effectiveness. We will review the various aspects of colorectal cancer from primary prevention to post-treatment follow-up. Scientific data are integrated in a pharmacoeconomic analysis.
Département de Médecine, Université de Liège.
G
G
Jerusalem
V
V
Bours
G
G
Fillet
D000970:Antineoplastic Agents / Q000191:economics* / Q000627:therapeutic use; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000517:prevention & control / Q000532:radiotherapy / Q000601:surgery; D003362:Cost-Benefit Analysis; D017850:Economics, Pharmaceutical; D005500:Follow-Up Studies; D017048:Health Care Costs; D006801:Humans; D011322:Primary Prevention / Q000191:economics; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000517:prevention & control / Q000532:radiotherapy / Q000601:surgery
D000970:Antineoplastic Agents